COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Komet Sales and Axerrio Combine to Expand Their Leading B2B Floral E-Commerce Network Across Europe and the Americas
Komet Sales, the leading software provider for the floral industry in the Americas, announces merger with Axerrio, a leading software provider for the floral industry in Europe. The merger aims to benefit customers by increasing access to new features and an expanded network of buyers and sellers -
COMMUNIQUÉ DE PRESSE
Cotec Holdings Corp. Provides Operational Overview and 2024 Key Targets
CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) reports 2023 operational highlights and 2024 targets. Initiated strategic investments, completed name change, and listed on TSXV. Focus on sustainable resource production and transformative technologies -
-
COMMUNIQUÉ DE PRESSE
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV -
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Bilfinger SE: EBITA margin and free cash flow in financial year 2023 exceeded outlook
Bilfinger SE reports EBITA margin for 2023 financial year exceeded outlook at 4.3% and free cash flow expected to be € 122 million, surpassing outlook by € 42 million. Revenue to be within outlook range. Mid-term targets confirmed -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Carl Zeiss Meditec AG agrees to launch share buyback program with volume of up to €150m
Carl Zeiss Meditec AG has approved a share buyback program of up to €150m, representing 1.7% of share capital, starting on 9 February 2024. The company may discontinue the program at any time -
COMMUNIQUÉ DE PRESSE
New evidence informs risk factors, diagnosis and care of patients with CVT stroke
American Heart Association releases a new scientific statement emphasizing the need to increase awareness of cerebral venous thrombosis (CVT) to improve recognition and initiate prompt medical treatment. The statement reviews the latest evidence and updates recommendations for diagnosing and managing CVT, focusing on advancements in treatment approaches -
COMMUNIQUÉ DE PRESSE
Original-Research: Avemio AG (von GBC AG): Kaufen
Avemio AG veröffentlicht vorläufige Zahlen für das abgelaufene Geschäftsjahr 2023 und bestätigt das Kauf-Rating trotz Umsatz- und Ergebnisrückgang. Neue Prognose und Kursziel von 32,00 EUR für 2024. Solide Kapitalausstattung und M&A-Wachstum geplant
